A 12-week, randomized, double-blind, dose-ranging, placebo-controlled study of asimadoline in subjects with irritable bowel syndrome.

Trial Profile

A 12-week, randomized, double-blind, dose-ranging, placebo-controlled study of asimadoline in subjects with irritable bowel syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2011

At a glance

  • Drugs Asimadoline (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2011 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
    • 15 May 2008 Results presented as a late-breaking oral presentation at DDW 2008, according to a Tioga Pharmaceuticals media release.
    • 26 Feb 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top